Utilidad de la PET-TC en la valoración de la respuesta precoz al tratamiento en el linfoma B difuso de celula grande. Resultados preliminares / Utility of the PET-CT in the evaluation of early response to treatment in the diffuse large B-cell lymphoma. Preliminary results

Objetivo. Valorar la utilidad de la PET-TC con FDG tras los primeros ciclos de quimioterapia en la predicción de la respuesta al tratamiento en pacientes con linfoma B difuso de célula grande. Metodologia. Se incluyeron 20 pacientes (edad media: 48), 16 en la estadificación inicial y 4 por recidiva. La PET-TC se realizó en tres tiempos: 1) Basal, 2) Tras el primer-tercer ciclo (valoración de respuesta precoz), y 3) Al finalizar el tratamiento (valoración de respuesta final). Los hallazgos de la valoración precoz fueron correlacionados con la valoración final y el seguimiento. La valoración de la respuesta se estableció según la disminución de la captación de las lesiones (SUVmax). En la valoración precoz el indicador de buena respuesta (IBR) fue la reducción del SUVmax > 50% o la desaparición. Al final del tratamiento se determinó la respuesta metabólica completa (RMC) en ausencia de focos. El seguimiento fue superior a los 19 meses, estableciendo progresión/recidiva o sin evidencia de enfermedad (SEE). Resultados. La valoración precoz fue IBR en 16/16 pacientes de estadificación inicial (100%) y en 2/4 de recidiva (50%). Al final del tratamiento, en el primer grupo 14/16 pacientes con IBR consiguieron RMC y 1/16 RMP; 14 continuaron SEE y uno recidivó. En el segundo grupo 2/2 pacientes con IBR consiguieron RMC; uno continuó SEE y otro recidivó. Conclusion. La PET-TC tras los primeros ciclos de quimioterapia es útil para monitorizar el tratamiento debido a su elevado valor predictivo negativo (87,5%), modificando la terapia precozmente en los no respondedores(AU)

Objective. To assess the role of FDG-PET/CT performed after the first cycles of chemotherapy in the prediction of response to treatment in patients with diffuse large B-cell lymphoma. Methods. Twenty patients (mean age: 48 years) were included, 16 initial staging and 4 relapse. All patients underwent PET/CT at 3 times: 1) Baseline, 2) After 1-3 cycles of chemotherapy (early response assessment), and 3) End of treatment (evaluation of final response). Early PET/CT findings were correlated to the end-treatment PET/CT and follow-up. The evaluation of the response was established according to the decrease in uptake of the lesions (SUVmax). In the early assessment, a good response indicator (GRI) was obtained when the lesion disappeared or had more than 50% reduction in SUVmax. At the end of the treatment, a complete metabolic response (CMR) was determined in negative PET scans. Follow-up was superior to 19 months and final outcome was established as progression/relapse or no evidence of disease (NED). Results. At the early treatment evaluation, 16/16 patients of initial staging (100%) and 2/4 of relapse (50%) achieved GRI. At the end of treatment evaluation, 14/16 patients of initial staging with GRI achieved CMR and 1/16 PMR: 14 were alive with NED in the follow-up while 1 relapsed. In the second group, 2/2 patients with GRI achieved CMR (100%): 1 continued with NED in the follow-up and another relapsed. Conclusion. FDG-PET/CT after the first cycles of chemotherapy is useful to monitor treatment due to its high negative predictive value (87.5%), using it to modify treatment early in the non-responders(AU)

Utility of the PET-CT in the evaluation of early response to treatment in the diffuse large B-cell lymphoma. Preliminary results.

OBJECTIVE: To assess the role of FDG-PET/CT performed after the first cycles of chemotherapy in the prediction of response to treatment in patients with diffuse large B-cell lymphoma. METHODS: Twenty patients (mean age: 48 years) were included, 16 initial staging and 4 relapse. All patients underwent PET/CT at 3 times: 1) Baseline, 2) After 1-3 cycles of chemotherapy (early response assessment), and 3) End of treatment (evaluation of final response). Early PET/CT findings were correlated to the end-treatment PET/CT and follow-up. The evaluation of the response was established according to the decrease in uptake of the lesions (SUVmax). In the early assessment, a good response indicator (GRI) was obtained when the lesion disappeared or had more than 50% reduction in SUVmax. At the end of the treatment, a complete metabolic response (CMR) was determined in negative PET scans. Follow-up was superior to 19 months and final outcome was established as progression/relapse or no evidence of disease (NED). RESULTS: At the early treatment evaluation, 16/16 patients of initial staging (100%) and 2/4 of relapse (50%) achieved GRI. At the end of treatment evaluation, 14/16 patients of initial staging with GRI achieved CMR and 1/16 PMR: 14 were alive with NED in the follow-up while 1 relapsed. In the second group, 2/2 patients with GRI achieved CMR (100%): 1 continued with NED in the follow-up and another relapsed. CONCLUSION: FDG-PET/CT after the first cycles of chemotherapy is useful to monitor treatment due to its high negative predictive value (87.5%), using it to modify treatment early in the non-responders.

[Calculation of the left ventricular ejection fraction. Comparison between 4 different instruments]. / Determinación de la fracción de eyección del ventrículo izquierdo realizada con 4 programas de cálculo distintos.

AIM: The aim of this study was to analyse the relationship between left ventricular ejection fractions (EF) obtained using four different instruments. MATERIAL AND METHODS: Eighty-five EF values were analysed. Gated acquisition was performed with the same gammacamera (SOPHA) using 99mTc-labelled red cells. Each EF was obtained using four processing systems: NXT (SOPHA), Entegra (Gems), Odyssey (Philips) and Esoft (Siemens), always working in automated mode. The paired student's t-test, Spearman correlation and Bland-Altman analysis were used to compare methods, and Deming regression was applied. RESULTS: Mean values and standard deviations for each program were: NXT: 61 +/- 9; Entegra: 60 +/- 10; Odyssey: 60 +/- 9; Esoft: 60 +/- 10. Although no significant differences were found as a whole and the values were linearly related, the methods are not interchangeable. CONCLUSIONS: The same program should be used in the follow-up of each patient, which is now easily achievable by means of the DICOM standard.

Determinación de la fracción de eyección del ventrículo izquierdo realizada con 4 programas de cálculo distintos / Calculation of the left ventricular ejection fraction. Comparison between 4 different instruments

Objetivo. Analizar la relación existente entre los valores de la fracción de eyección (FE) del ventrículo izquierdo obtenidos mediante ventriculografía isotópica en equilibrio utilizando cuatro equipos de procesado distintos. Material y métodos. Se han estudiado 85 FE. Las adquisiciones se realizaron en una única gammacámara (Sopha®) mediante sincronización con el electrocardiograma (ECG) y utilizando hematíes marcados con Tc-99m. Se ha obtenido cada una de las FE por cuatro sistemas de procesado: NXT (Sopha®), Entegra (Gems®), Odissey (Philips®) y Esoft (Siemens®). El modo empleado por defecto era el de cálculo automático. Se aplicó la prueba de comparación de medias para datos apareados agrupando las 4 series de datos dos a dos. Asimismo, se buscó la correlación de Spearman y se aplicó la prueba de Bland-Altman para intercambiabilidad y se analizó su regresión por el método de Deming. Resultados. Los valores medios ± desviación estándar según cada programa fueron: NXT: 61 ± 9, Entegra: 60 ± 10, Odyssey: 60 ± 9, Esoft: 60 ± 10. No se han detectado globalmente diferencias, pero los 4 programas generan valores no intercambiables entre sí. Conclusiones. Aunque linealmente relacionados y sin diferencias significativas, se concluye que si se han de comparar estudios de un mismo paciente se emplee el mismo programa, cosa actualmente factible mediante el formato DICOM

Aim. The aim of this study was to analyse therelationship between left ventricular ejection fractions (EF) obtained using four different instruments.Material and methods. Eighty-five EF values were analysed. Gated acquisition was performed with the same gammacamera (SOPHA®) using 99mTc-labelled red cells. Each EF was obtained using four processing systems: NXT (SOPHA®), Entegra (Gems®), Odyssey (Philips®) and Esoft (Siemens®), always working in automated mode.The paired student’s t-test, Spearman correlation andBland-Altman analysis were used to compare methods,and Deming regression was applied. Results. Mean values and standard deviations for each program were: NXT: 61 ± 9; Entegra: 60 ± 10; Odyssey: 60 ± 9; Esoft: 60 ± 10.Although no significant differences were found as a wholeand the values were linearly related, the methods are not interchangeable. Conclusions. The same program should be used in the follow- up of each patient, which is now easily achievable by means of the DICOM standard (AU)